Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

How azacitidine works

Share :

ASH 50th annual meeting 2008

6 - 9 Dec 2008
Published: 19 Feb 2009
Views: 21025
Rating:
Save
Dr Lewis Silverman - Myelodysplastic Syndrome & Myeloproliferative Disease Center, New York
How azacitidine / vidaza works, epigenetics and vidaza, the difference vidaza makes for patients. Interviewed at ASH 2008.

Related Videos

ZUMA-7: Axi-cel is superior to standard of care across common prognostic...
Dr Fred Locke - Moffitt Cancer Center, Tampa, USA
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )
23 Dec 2022
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of...
Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022
Effective treatment of low risk acute GVHD with itacitinib monotherapy
Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA
Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )
21 Dec 2022
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival...
Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma ( Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA )
12 Oct 2022
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Pd in Difficult-to-Treat Patients with RRMM ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
11 Jul 2022
The advances in the management of patients with Hodgkin lymphoma and non...
Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute...
The advances in the management of patients with Hodgkin lymphoma and non-Hodgkin lymphoma ( Dr Eduardo Sotomayor - H. Lee Moffitt Cancer Center & Research Institute, Florida, USA )
9 Jul 2022
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly...
Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain
Axicabtagene ciloleucel provides superior EFS vs standard of care in elderly with relapsed/refractory large B-cell lymphoma ( Dr Anna Sureda - Blood Cell Barcelona Hematology Institute, Barcelona, Spain )
1 Jul 2022
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial
Dr Maximilian Merz - Leipzig University, Leipzig, Germany
Isatuximab + Kd in RRMM: Depth of Response Results From the IKEMA Trial ( Dr Maximilian Merz - Leipzig University, Leipzig, Germany )
28 Jun 2022
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic...
Dr Carol Moreno - University of Barcelona, Barcelona, Spain
Ibrutinib plus venetoclax for 1-L treatment of CLL and small lymphocytic lymphoma shows a clinically meaningful PFS ( Dr Carol Moreno - University of Barcelona, Barcelona, Spain )
21 Jun 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation